1h Free Analyst Time
The active pharmaceutical ingredient (API) market in India is forecasted to grow by USD 11.18 billion during 2024-2029, accelerating at a CAGR of 7.4% during the forecast period. The report on the active pharmaceutical ingredient (API) market in India provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of type ii drug master files (DMF), growing emphasis on biosimilars manufacturing, and growing need to focus on core competencies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The active pharmaceutical ingredient (API) market in India is segmented as below:
By Manufacturing Type
- Captive APIs
- Contract APIs
By Type
- Innovative APIs
- Generic APIs
By Product Type
- Prescription
- Over-the-counter (OTC)
By Application
- Cardiovascular diseases (CVDs)
- Oncology
- Infectious diseases
- Diabetes
- Others
By Geographical Landscape
- APAC
The report on the active pharmaceutical ingredient (API) market in India covers the following areas:
- Active Pharmaceutical Ingredient (API) Market in India sizing
- Active Pharmaceutical Ingredient (API) Market in India forecast
- Active Pharmaceutical Ingredient (API) Market in India industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Manufacturing Type
9 Market Segmentation by Type
10 Market Segmentation by Product Type
11 Market Segmentation by Application
12 Customer Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the active pharmaceutical ingredient (API) market in india: AbbVie Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Inc., Divis Laboratories Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Granules India Ltd., Hetero Labs Ltd., Ind-Swift Laboratories Ltd., IOL Chemicals and Pharmaceuticals Ltd., Ipca Laboratories, J. B. Chemicals and Pharmaceuticals Ltd, Jubilant Pharmova Ltd., Laurus Labs Ltd., Lupin Ltd., Solara Active Pharma Sciences Ltd, Sun Pharmaceutical Industries Ltd., SUVEN PHARMACEUTICALS LTD., and Torrent Pharmaceuticals Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is paradigm shift in api manufacturing."
According to the report, one of the major drivers for this market is the increasing number of type ii drug master files (DMF).
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aurobindo Pharma Ltd.
- Cadila Pharmaceuticals Ltd.
- Cipla Inc.
- Divis Laboratories Ltd.
- Dr Reddys Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Granules India Ltd.
- Hetero Labs Ltd.
- Ind-Swift Laboratories Ltd.
- IOL Chemicals and Pharmaceuticals Ltd.
- Ipca Laboratories
- J. B. Chemicals and Pharmaceuticals Ltd
- Jubilant Pharmova Ltd.
- Laurus Labs Ltd.
- Lupin Ltd.
- Solara Active Pharma Sciences Ltd
- Sun Pharmaceutical Industries Ltd.
- SUVEN PHARMACEUTICALS LTD.
- Torrent Pharmaceuticals Ltd.
